TABLE 3.
HSV-2 peptides recognized by HSV-2+ subjectsa
| HSV-2+ Subject | HSV-2 ORF | Peptide | Sequenceb | CD4 or CD8c |
|---|---|---|---|---|
| 2 | UL46 | UL46397–407 | KSWFGAALAPD | ndd |
|
| ||||
| 5 | UL46 | UL46625–635 | VRVYENICLRR | CD4 |
| gD-2 | multiplee | CD4f | ||
|
| ||||
| 7 | ICP0 | ICP0123–137 | VCAVCTDEIAPPLRC | nd |
| ICP0 | ICP0135–149 | LRCQSFPCLHPFCIP | nd | |
| ICP4 | ICP41009–1023 | LGNRLCGPATAAWAG | CD8 | |
| ICP4 | ICP41169–1183 | MSPREYRRAVLPALD | CD4/CD8 | |
| UL11 | UL111–15 | MGLAFSGARPCCCRH | CD4 | |
| gB-2 | gB-2513–527 | HVNDMLGRIAVAWCE | CD4 | |
|
| ||||
| 8 | ICP4 | ICP4533–547 | VAMSRRYDRAQKGFL | CD4 |
|
| ||||
| 10 | gD-2 | multiple | nd | |
|
| ||||
| 11 | UL19 | UL191237–1251 | PFAATANPWASQRFS | CD4 |
|
| ||||
| 12 | UL46 | UL46621–635 | EIPWVRVYENICLRR | CD4 |
| gD-2 | multiple | CD4f | ||
|
| ||||
| 13 | gD-2 | multiple | CD4f | |
| ICP0 | multiple | nd | ||
| UL39 | UL39957–971 | SMMKHGLRNSQFIAL | nd | |
| UL29 | UL29921–936 | SRRPPSVQAAAAWAPQ | nd | |
|
| ||||
| 14 | UL39 | UL39957–971 | SMMKHGLRNSQFIAL | nd |
| UL29 | UL29921–936 | SRRPPSVQAAAAWAPQ | nd | |
|
| ||||
| 15 | gB-2 | gB-2140–152 | IAVVFKENIAPY | CD4 |
| UL39 | multiple | nd | ||
|
| ||||
| 16 | UL49 | UL49249–263 | KNLLQRANELVNPDA | CD4 |
| ICP0 | multiple | nd | ||
| UL39 | multiple | nd | ||
| gB-2 | gB-2276–291 | YPYDEFVLATGDFVY | CD4 | |
| gB-2 | gB-2849–859 | YMALVSAMERT | CD4 | |
| gD-2 | multiple | nd | ||
|
| ||||
| 17 | UL46 | UL4669–83 | GADRSVRLAARHHNT | nd |
| UL39 | multiple | nd | ||
| gB-2 | gB-2277–287 | YPYDEFVLATG | nd | |
|
| ||||
| 18 | gD-2 | multiple | CD4f | |
| UL46 | UL46249–263 | RLGPADRRFVALSGS | nd | |
| UL46 | UL46621–635 | EIPWVRVYENICLRR | nd | |
|
| ||||
| 19 | ICP4 | ICP41013–1023 | LCGPATAAWAG | CD8 |
| gD-2 | multiple | nd | ||
| UL46 | UL46670–681 | SPPGATRAPDPG | nd | |
| ICP0 | ICP0638–651 | SASGAGERRETSLGP | nd | |
| ICP0 | ICP0650–664 | LGPRAAAPRGPRKCA | nd | |
|
| ||||
| 20 | UL19 | UL191235–1249 | PFAATANPWASQRFS | CD4 |
|
| ||||
| 21 | gD-2 | gD-2273–287 | YTSTLLPPELSDTTN | CD4 |
|
| ||||
| 22 | UL46 | UL46621–635 | EIPWVRVYENICLRR | CD4 |
| gD-2 | multiple | nd | ||
|
| ||||
| 23 | UL25 | UL25405–419 | DRLDNRLQLGMLIPG | CD8 |
|
| ||||
| 24 | ICP0 | ICP0127–137 | CTDEIAPPLRC | CD8 |
| ICP0 | ICP0638–651 | SASGAGERRETSLGP | nd | |
| ICP0 | ICP0650–664 | LGPRAAAPRGPRKCA | nd | |
| ICP4 | ICP4429–443 | QYALITRLLYTPDAE | nd | |
| ICP4 | ICP4441–455 | DAEAMGWLQNPRVAP | CD4 | |
| UL39 | UL391013–1027 | KELERTFGGKRLLDA | nd | |
|
| ||||
| 25 | ICP4 | ICP41169–1183 | MSPREYRRAVLPALD | CD4 |
| UL19 | UL19828–838 | GVRFDRVYATL | CD8 | |
| UL19 | UL19789–803 | ARAADAADDRPHRPA | CD4 | |
| UL27 | gB-2137–152 | YTEGIAVVFKENIAPY | CD4/CD8 | |
a
Individual HSV-2 peptides recognized by T cells from HSV-2+ subjects were determined by deconvoluting the HSV-2 peptide pools.
b
When sequential overlapping 15 mers within an ORF were positive, we list the 11 amino acid sequence shared between the 2 peptides.
c
Phenotype of responding T cells was determined by ICS and flow cytometry.
d
Not determined.
e
In some cases multiple array pools were positive indicating responses to multiple epitopes within an ORF and thus a single epitope could not be deduced.
f
The phenotype of responding T cells was performed using the gD-2 peptide pool to stimulated PBMC as opposed to using individual gD-2 peptides.